Article
When drugs have failed, transurethral needle ablation (TUNA) has shown to be an effective long-term option for men suffering from BPH, according to recently published data.
Expert discusses the promise of emerging MISTs for BPH
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk